TITLE

Plasma 9α,11β-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma

AUTHOR(S)
Bochenek, G.; Niżankowska, E.; Gielicz, A.; Swierczyńska, M.; Szczeklik, A.
PUB. DATE
June 2004
SOURCE
Thorax;Jun2004, Vol. 59 Issue 6, p459
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Prostaglandin D2 (PGD2) is a major cyclooxygenase product generated by activated most cells during an allergic response. Assessment of PGD2 and its metabolites in patients with asthma has mostly been performed in urine, bronchoalveolar lavage fluid and induced sputum, whereas human plasma determinations have been performed only sporadically. Methods: In 32 patients with allergic asthma and 50 healthy non-allergic controls, baseline plasma and urinary levels of 9α, 11β-PGF2, a primary PGD2 metabolite, were assessed by gas chromatography/mass spectrometry. Serum tryptase levels were measured by fluoroenzyme immunoossay and urinary leukotriene E4 (LTE4) by ELISA. In a subgroup of 10 asthmatics (randomly selected from the 32 study patients) in whom bronchial allergen challenges with specific allergens (Dermatophagoides pteronyssinus, n = 4, mixed grass pollens, n = 6) were carried out, measurements were taken both before and after provocation. Results: At baseline no significant differences between mean plasma and urinary levels of the PGD2 metabolite and serum tryptase levels were found in asthmatics or controls. Asthmatic patients had significantly higher urinary LTE4 levels. Allergen challenge resulted in a significant early increase in the mean plasma 9α 11β-PGF2 level and only a borderline but significant increase in the urinary 9α 11β- PGF2 level within 2 hours after provocation. The challenge did not produce statistically significant changes in serum tryptase levels.
ACCESSION #
13599825

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics